Hi, I'm Dr. Jason Weston from MD Anderson Cancer Center in Houston, Texas. We're at the ASH 2023 meeting where we're excited to see all the latest advances where we can help our patients with lymphoma even more, both in 2023 and for years to come. I'm honored to present on behalf of my colleagues our clinical trial from MD Anderson where we're looking at patients with aggressive lymphomas, specifically diffuse large B cell lymphoma for patients that are newly diagnosed. And the standard treatment for this frontline therapy for aggressive lymphomas for generation has been a combination of chemotherapy drugs and immune therapy drugs called R-CHOP. Our clinical trial is evaluating if we could start with novel targeted therapies, modern therapies, not 1970s chemotherapies, and use these targeted therapies in combination for the first four cycles. If patients have a good response, a complete response, meaning their PET scan is already clear prior to any chemotherapy, they would receive less for the current cohort, less chemotherapy and for the cohort running now, no chemotherapy for what has been a disease. Six cycles of CHOP has been the standard for close to 40 years. This clinical trial is being presented today at the ASH meeting and what we're going to nearly two thirds of patients on this clinical trial were able to achieve a complete response prior to any chemotherapy. Now this is exciting information. This is not ready to change practice tomorrow for all patients with this disease. However, it does show the power of clinical trials and the idea of getting tomorrow's therapies today is something that I think is one of the wonderful benefits of considering participating in a clinical trial. So if you are diagnosed with this disease, if your doctor is recommending standard treatments, that may be very appropriate, but it's also appropriate in my opinion to ask, is a clinical trial a good idea for me and if so, how could I participate? Thank you.
